Clinical trials: Semaglutide
Obesity
A Research Study to See How Well CagriSema Compared to Tirzepatide Helps People With Obesity Lose Weight
This study will look at how well CagriSema compared to Tirzepatide helps people lower their body weight. CagriSema is a new investigational medicine developed by Novo Nordisk that combines Cagrilintide and Semaglutide.
- Trial name
- NCT06131437
- Testing
- Cagrilintide, Semaglutide, Tirzepatide
- Where
- 46 sites in United States
- Volunteers
- 809 people
- Sponsor
- Novo Nordisk A/S
Obesity
A Phase III Study Comparing the Weight Loss Effects of Semaglutide Injection and Wegovy®
The purpose of the study is to compare the effect on body weight in subjects taking semaglutide injection or subjects taking Wegovy®.
- Trial name
- NCT06633783
- Testing
- Semaglutide
- Where
- 14 sites in China
- Volunteers
- 370 people
- Sponsor
- Hangzhou Jiuyuan Gene Engineering Co. Ltd.,
Diabetes Mellitus, Type 2
A Research Study Looking at How Oral Semaglutide Works in People With Type 2 Diabetes in the United Kingdom, as Part of Local Clinical Practice
The purpose of the study is to collect information on how Rybelsus® works in people with type 2 diabetes and to see if Rybelsus® can lower their blood sugar levels.
- Trial name
- PIONEER REAL (NCT04862923)
- Testing
- Oral semaglutide
- Where
- United Kingdom
- Volunteers
- 336 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Research Study on How Well Semaglutide Works in Adolescents With Overweight or Obesity
This study will look at the change in teenagers' body weight from the start to the end of the study. This is to compare the effect on body weight in teenagers taking semaglutide (a new medicine) and teenagers taking "dummy"…
- Trial name
- NCT04102189
- Testing
- Semaglutide
- Where
- 51 sites in United States, Austria and 6 more
- Volunteers
- 201 people
- Sponsor
- Novo Nordisk A/S
Obesity
SYNCHRONIZE®-START- A Study to Test Whether Survodutide Helps People Living With Overweight or Obesity Who do Not Have Diabetes to Lose Weight
This study is open to adults with overweight or obesity. People can join the study if they have a body mass index (BMI) of 30 kg/m² or more, or a BMI of 27 kg/m² or more with at least one weight- related health problem.
- Trial name
- NCT07855900
- Testing
- Survodutide
- Where
- 2 sites in United States
- Volunteers
- 350 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 2
A Trial to Assess the Pharmacokinetics, Safety and Tolerability of Semaglutide in Healthy Chinese Subjects
The main purpose of the trial is to assess the pharmacokinetics of semaglutide (i.e. the way the drug is distributed in the body over a period of time) following once-weekly administration of semaglutide in healthy Chinese…
- Trial name
- NCT03288740
- Testing
- Semaglutide 0.5 mg, Semaglutide 1.0 mg
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
Dose-finding of Semaglutide Administered Subcutaneously Once Daily Versus Placebo and Liraglutide in Subjects With Type 2 Diabetes
This trial is conducted globally. The aim of this trial is to investigate dose-finding of semaglutide administered subcutaneously once daily versus placebo and liraglutide in subjects with type 2 diabetes
- Trial name
- NCT02461589
- Testing
- semaglutide, liraglutide
- Where
- 150 sites in United States, Austria and 8 more
- Volunteers
- 706 people
- Sponsor
- Novo Nordisk A/S
Overweight, Obesity
A Clinical Study of Semaglutide Nasal Spray in Overweight or Obese Adults
The specific aim of this study is to examine the Safety, Tolerability and Pharmacokinetic of Semaglutide Nasal Spray compared with placebo and positive control in Adult Overweight or Obese Participants.
- Trial name
- NCT07465965
- Testing
- Semaglutide Nasal Spray, Semaglutide Injection
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- Shanghai World Leader Pharmaceutical Co., Ltd.
Diabetes Mellitus, Type 2
A Research Study Looking at How Semaglutide Works in People With Type 2 Diabetes in France, as Part of Local Clinical Practice (SURE FRANCE)
The purpose of the study is to collect information on how semaglutide works in real world patients. Participants will get semaglutide prescribed by their study doctor. The study will last for about 6 to 8 months.
- Trial name
- SURE FRANCE (NCT04083820)
- Testing
- semaglutide
- Where
- 53 sites in France
- Volunteers
- 521 people
- Sponsor
- Novo Nordisk A/S
Diabetes, Diabetes Mellitus, Type 2
A Trial Investigating the Effect of Semaglutide on Hypoglycaemic Counterregulation Compared to Placebo in Subjects With Type 2 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the effect of semaglutide on hypoglycaemic counter-regulation compared to placebo in subjects with type 2 diabetes.
- Trial name
- NCT02147431
- Testing
- semaglutide
- Where
- Austria
- Volunteers
- 38 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
A Study Comparing the Dulaglutide Pen and the Semaglutide Pen
In this study participants will try out two different types of drug injection pens (dulaglutide and semaglutide) on a practice pad and decide which device they prefer. No study drug will be administered.
- Trial name
- NCT03724981
- Testing
- Dulaglutide Pen, Semaglutide Pen
- Where
- 14 sites in United States
- Volunteers
- 312 people
- Sponsor
- Eli Lilly and Company
Obesity, Muscle Loss
A Study of the Effect of (S)-Pindolol Benzoate (ACM-001.1) on Lean Body Mass (LBM) in Obese Patents During (PROACT 1), and Post-semaglutide Therapy (PROACT 2)
Semaglutide is approved for weight management (weight loss and weight maintenance) in adult obese patients. Drug treatments like semaglutide that result in weight-loss can also decrease muscle mass.
- Trial name
- PROACT (NCT07101939)
- Testing
- (S)-pindolol benzoate, Semaglutide
- Where
- 7 sites in Serbia
- Volunteers
- 120 people
- Sponsor
- Actimed Therapeutics Ltd
Healthy Volunteers, Overweight
First Research Study to Look at How Two Medicines, NNC0480-0389 and Semaglutide, Work Together in Healthy People, in People With High Body Weight and in People With Diabetes
The purpose of this study is to investigate how safe, and how well tolerated, the new study drug NNC0480-0389 is when it is given together with semaglutide.
- Conditions
- Healthy Volunteers, Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- NCT04259801
- Testing
- NNC0480-0389, Semaglutide
- Where
- Netherlands
- Volunteers
- 152 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Healthy Volunteers, Diabetes Mellitus, Type 2
Comparison of Injection Site Pain Experience for Semaglutide and Dulaglutide sc
This study in healthy men and women looks at the injection site experience of semaglutide and dulaglutide given subcutaneously (s.c., under the skin).
- Conditions
- Healthy Volunteers, Diabetes Mellitus, Type 2, Overweight, Obesity
- Trial name
- NCT04189848
- Testing
- Semaglutide, Dulaglutide
- Where
- Netherlands
- Volunteers
- 104 people, healthy volunteers welcome
- Sponsor
- Novo Nordisk A/S
Obesity
A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term
This study will look at how well CagriSema helps people living with obesity to lose weight and maintain the weight loss long-term.
- Trial name
- NCT07011667
- Testing
- CagriSema (Cagrilintide B and Semaglutide I)
- Where
- 47 sites in United States
- Volunteers
- 609 people
- Sponsor
- Novo Nordisk A/S
Longevity, Quality of Life
Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures
The goal of this clinical study has two objectives. The Primary Objective is to evaluate the effectiveness of microdosed GLP-1 receptor agonists in improving measures of health, quality of life, and longevity.
- Conditions
- Longevity, Quality of Life, Mood, Inflammation
- Trial name
- NCT07092605
- Testing
- GLP-1
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- AgelessRx
Diabetes, Diabetes Mellitus, Type 2
Effect of Oral Contraceptives After Administration of Semaglutide in Subjects With Type 2 Diabetes
This clinical trial is conducted in Europe. The purpose of the trial is to investigate the influence on the pharmacokinetics (the rate at which the trial drug is eliminated from the body) of an oral contraceptive combination drug…
- Trial name
- NCT01324505
- Testing
- semaglutide, Microgyn®
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes Mellitus
Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus
To evaluate the similarity of the efficacy and safety of semaglutide injection (HD1916) vs. Ozempic® in patients with type 2 diabetes mellitus (T2DM) with poor blood glucose control after metformin treatment.
- Trial name
- NCT06161844
- Testing
- semaglutide injection (HD1916), Ozempic®
- Where
- China
- Volunteers
- 506 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Overweight and Obesity, Healthy
A Study to Evaluate the Safety and Efficacy of NG101 in Adult Participants Receiving a Glucagon-like Peptide-1 (GLP-1) Agonist
Adult participants with BMI between 22 - 35 kg/m2 will be enrolled and randomized to receive either NG101 (20 mg twice daily [BID]) or placebo for 5 days beginning on Day 1.
- Trial name
- NCT06500429
- Testing
- NG101, Semaglutide Injectable Product
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Neurogastrx, Inc.
Obesity
A Research Study to See How Well CagriSema Helps People With Excess Body Weight Lose Weight
This study has 2 parts: First part is the main study and second part is the extension study. During the main study participants will receive 1 of 4 study medicines.
- Trial name
- REDEFINE 1 (NCT05567796)
- Testing
- Cagrilintide, Semaglutide
- Where
- 256 sites in United States, Argentina and 21 more
- Volunteers
- 3,400 people
- Sponsor
- Novo Nordisk A/S